在2025年对甲状腺过敏喷雾PL-14进行临床试验时,生物技术公司Polyrizon与Eurufins合作。 Biotech firm Polyrizon partners with Eurofins for 2025 clinical trial of allergy nasal spray PL-14.

一家生物技术公司Polyrizon与Europons CDIMO Amatsiaquitaine S.A.S.签署了一份制造交易。 A biotech company, Polyrizon, has signed a manufacturing deal with Eurofins CDMO Amatsiaquitaine S.A.S. 为2025年对过敏阻塞鼻腔喷雾PL-14进行临床试验生产材料。 to produce materials for a 2025 clinical trial of its allergy-blocking nasal spray, PL-14. 伙伴关系旨在确保高质量的生产既符合美国标准,也符合欧洲标准,推动实现Polyrizon解决与过敏相关的健康问题的目标。 The partnership aims to ensure high-quality production meeting both U.S. and European standards, advancing Polyrizon's goal of addressing allergy-related health issues.